(Total Views: 173)
Posted On: 10/04/2021 10:10:48 AM
Post# of 127145

$RDHL News Article - RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients https://marketwirenews.com/news-releases/redh...67644.html


My Twitter: WhyteStocks